Trial Profile
An Extension to a Phase II Study to Determine the Safety and Anti-Leukemic Effects of STI571 in Adult Patients With Philadelphia Chromosome Positive Leukemia Including Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Accelerated Phase Chronic Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Imatinib (Primary)
- Indications Leukaemia
- Focus Therapeutic Use
- Sponsors Novartis
- 15 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 23 Apr 2013 Planned End Date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 27 Apr 2012 Planned End Date changed from 1 Dec 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.